Pomerantz Law Firm Launches Investigation into Inovio Pharmaceuticals for Potential Investor Misconduct

Investor Alert: Investigation into Inovio Pharmaceuticals

On January 8, 2026, Pomerantz LLP announced an investigation on behalf of investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO). Concerns have arisen regarding possible securities fraud and other unlawful practices connected with the company and its leadership. Investors seeking accountability are encouraged to reach out to Pomerantz LLP.

Background on Inovio Pharmaceuticals

Inovio, a biotechnology company known for developing DNA-based immunotherapies and vaccines, has recently been in the spotlight due to scrutiny from the U.S. Food and Drug Administration (FDA). On December 29, 2025, the FDA accepted Inovio's Biologics License Application (BLA) for its treatment INO-3107, aimed at addressing recurrent respiratory papillomatosis. This acceptance, however, came with a significant caveat: the agency deemed that Inovio fell short of providing sufficient information to qualify for the accelerated approval pathway that the company sought.

As a result of this announcement, Inovio's stock price experienced a steep decline, plummeting by 24.45%, dropping to $2.29 per share. This dramatic downturn has raised alarms among investors who are now questioning the company’s transparency and compliance with regulatory standards.

Potential Impact on Investors

The implications of the FDA's statements and the subsequent share price slump have prompted Pomerantz LLP to look into possible negligence or misconduct on the part of Inovio's executive team. Shareholders may have been misled regarding the approval status of their product, and the firm is determined to uncover the facts surrounding this issue.

Pomerantz LLP has a long-standing reputation as a leader in securities class action litigation, having recovered significant damages for class members over its extensive history. The firm's dedication to advocating for victims of securities fraud echoes throughout its more than 85 years of existence. If you believe you may have a claim as an investor in Inovio Pharmaceuticals, contacting the firm may be a critical step in seeking justice and potential compensation for your losses.

What Comes Next

Inovio has announced plans to schedule discussions with the FDA to explore the possibility of pursuing accelerated approval despite the recent setbacks. This situation remains fluid, and any future developments could impact investor sentiments.

Investors are encouraged to stay informed and vigilant regarding updates on the investigation and Inovio's negotiations with the FDA. More information is available directly from Pomerantz LLP through Danielle Peyton, who can be reached via email or phone for those looking for guidance.

Investors should remain aware that past successes for Pomerantz do not guarantee similar outcomes, underscoring the importance of understanding the specific circumstances surrounding each case.

For anyone affected, vigilance and understanding your rights as an investor during these turbulent times could be pivotal—Pomerantz LLP is poised to fight for accountability where it is due.